FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026

oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]

AI Summary: The FDA released draft guidance creating a regulatory pathway to speed individualized and N-of-1 cell and gene therapies for ultra‑rare diseases. The framework clarifies evidence expectations, manufacturing and safety-monitoring options, and trial design flexibility to help get bespoke treatments from bench to bedside faster — no miracles promised, just fewer bureaucratic speed bumps.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 1 month

FDA makes one pivotal trial the default for drug approvals / 3 months

FDA refuses to review Moderna mRNA flu vaccine application / 3 months

FDA rejects Atara cell therapy for Epstein–Barr virus complications / 4 months

Boehringer gains fast approval for first‑line lung cancer drug via voucher program / 3 months

FDA commissioner Marty Makary resigns amid mounting scrutiny / 19 days

World Cancer Day Global Awareness Campaign / 3 months